Browse by category

Individualised obesity therapy - tailoring interventions to a person's phenotypes

Phenotype-tailored lifestyle interventions may result in significant weight loss according to the results from a pilot study of 165...

EMA reviewing data after reports of suicidal thoughts and thoughts of self-harm after taking GLP-1a

The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) is reviewing data on the risk of suicidal...

Low adherence and increased cost in first year of taking GLP-1a drugs for weight loss

An analysis of real-world integrated pharmacy and medical claims data by leading pharmacy benefit manager Prime Therapeutics and Magellan...

NICE needs more evidence before recommending tirzepatide for T2DM treatment

The UK’s National Institute for Health and Care Excellence (NICE) has not recommended tirzepatide (Mounjaro, developed by Eli Lilly) in...

Bariatric surgery reduces mortality in patients with obesity and sleep apnoea

Bariatric surgery was associated with a 42% lower risk of major adverse cardiovascular events (MACE), including heart failure, heart...

Despite lowering BMI threshold for eligibility, access to surgery remains low

Despite patient eligibility for bariatric surgery expanding over the last decade and its safety and effectiveness even further...

Metabolic surgery results in fewer heart attacks, strokes and death among patients with diabetes

Patients with diabetes and a history of metabolic surgery had significantly fewer heart attacks, strokes, hospitalisations and death,...

T2DM remains in remission six years after RYGB regardless of weight loss

More than half of patients (51%) with type 2 diabetes and a history of metabolic surgery experienced remission of their diabetes even if...

Once-daily oral nonpeptide GLP-1-RA achieved up to 14.7% mean weight reduction at 36 weeks

Phase 2 data for orforglipron (12 mg, 24 mg, 36 mg or 45 mg), a nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, has...

GLP-1-RA: Pfizer to continue danuglipron but discontinue lotiglipron

Pfizer will continue to progress its first full agonist oral glucagon-like peptide-1 receptor agonist (GLP-1-RA) candidate - danuglipron...

1 2

4 5

Reduced complication-related costs and enhanced patient recovery using the Ezisurg Endostapler

2 days ago

Fractyl unveils promising preclinical data demonstrating safety and feasibility of local delivery of RJVA-001 Rejuva Smart GLP-1 Pancreatic Gene Therapy

5 days ago

Researchers to develop BIOSYNC wireless bioelectronic device to treat obesity and diabetes

6 days ago

Browse by category

Browse by tag

Weekly Digest

Get a round-up of the main headlines from Bariatric News, directly to your inbox each week.

Get in touch!
Email: info@bariatricnews.net